Dong 2013.

Methods	Study design: randomised clinical trial Study duration: May 2007 to March 2011 Duration of follow‐up: 6 months Setting: hospital
Participants	Inclusion criteria: diagnosed as large HCC (tumour maximal diameter > 5 cm) by liver biopsy; single tumour Age (mean ± SD, range): TACE + RFA: 57.3 ± 3.2 years; TACE alone: 58.4 ± 2.9 years Male (n/total): TACE + RFA: 14/22; TACE alone: 16/22 Tumour diameter (mean ± SD): TACE + RFA: 8.7 ± 2.1 cm; TACE alone: 9.1 ± 2.5 cm Serum level of AFP: Abnormal: TACE + RFA: 21 patients; TACE alone: 19 patients Normal: TACE + RFA: 1 patients; TACE alone: 3 patients
Interventions	TACE + RFA group (n = 22): TACE: the combination of hepatic arterial infusion chemotherapy and hepatic artery embolisation RFA: ultrasound‐guided RFA TACE group (n = 22): The combination of hepatic arterial infusion chemotherapy and hepatic artery embolisation
Outcomes	Serum level of AFP Clinical efficacy: measured by image examinations at 6 months after treatment Adverse events
Notes	Country of study: China Source of funding: none There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.